Nucryst: enrollment complete in second phase 2 clinical trial of topical cream for atopic dermatitis

By Lisa Kerner

Erie, Pa., April 27 - Nucryst Pharmaceuticals Corp. completed patient enrollment in the second phase 2 clinical trial of a topical cream formulation of its nanocrystalline silver (NPI 32101) for the treatment of atopic dermatitis, a common form of eczema.

A total of 409 patients, aged two to 17 years of age, with mild to moderate eczema, are enrolled for up to 12 weeks of treatment in a double-blind, randomized, placebo-controlled study at 29 sites in the United States and Canada.

Patients are being treated with one of three cream formulations, either 1% or 2% concentrations of NPI 32101 or with a placebo.

Dermatologists will evaluate the effectiveness of topical NPI 32101 in improving the signs and symptoms of atopic dermatitis as well as the product's safety.

Nucryst said results of the study are expected by the end of 2006.

"We see great potential for NPI 32101 as a well-tolerated treatment for atopic dermatitis," president and chief executive officer Scott H. Gillis said in a company news release.

"In our preclinical studies, NPI 32101 in a cream formulation has demonstrated the ability to address inflammation that is a hallmark of atopic dermatitis."

Located in Wakefield, Mass., Nucryst develops medical products that fight infection and inflammation using nanocrystalline silver technology.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.